Avtor/Urednik		Zver, Aleksandra; Zver, Samo; Mlakar, Uroš; Preložnik-Zupan, Irena; Pretnar, Jože
Naslov		Zdravljenje bolnikov z diseminiranim plazmocitomom s tandemsko avtologno presaditvijo krvotvornih matičnih celic v Sloveniji
Prevedeni naslov		Treatment of multiple myeloma patients with tandem autologous hematopoetic stem cell transplantation in Slovenia
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 77, št. Suppl 1
Leto izdaje		2008
Obseg		str. I-75-80
Jezik		slo
Abstrakt		Background Multiple myeloma (MM) is an incurable disease and autologous hematopoetic stem cell transplantation (HSCT) is the most effective treatment modality. It’s effectivity is even higher, when we treat patients with two consecutive autologous HSCT. We present our experiences with tandem autologous HSCT in patients with MM. Methods During the period from 1. 1. 2003 untill 1. 11. 2007 we treated 62 MM patients. After induction therapy and stem cell collection we performed tandem autologous HSCT within six-month period. Treatment results were followed with biochemical parameters, monoclonal globulin peak and free light chains in serum. Results Complete remission after induction was achieved in 1/62 (1,6%) patients, after first HSCT in 6/62 (9.6%) and after second HSCT in 24/62 (39%) patients. Putting together CR and PR (partial remission) at three treatment steps, this was achieved in 32/62 (51%), 51/62 (82 %) and 55/62 (89%) patients. 1/62 (1.6%) patients died during the treatment. Mean time until relaps was 31,4 months (24.7‐38.2 months; 95% confidence interval) and for survival 50,2 months (44.0‐56.4 months; 95% confidence interval). Median relaps time was 23 months (5.6‐40.4 months; 95% confidence interval), and median time for survival was not reached yet. Conclusions Treatment of MM patients with tandem autologous HSCT is highly effective treatment modality and our center’s experiences/results are comparable with other transplant centers worldwide. But in Slovenija, we must strictly perform all HSCT related investigations as well as improve reporting all treatment related data to transplant center.
Deskriptorji		LEUKEMIA, LYMPHOCYTIC, CHRONIC MUTATION IMMUNOGLOBULINS, HEAVY-CHAIN POLYMERASE CHAIN REACTION BASE SEQUENCE ELECTROPHORESIS, POLYACRYLAMIDE GEL